GlassScriptPhysician profile
Amrita De Patel
NPI 1144455759
$1,456.53
in general payments reported to CMS, 2019-2025
21 companies · $418 in 2025
The $418 reported for 2025 was more than what 75% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.14 · 2020: $29.21 · 2021: $24.65 · 2022: $503 · 2023: $127 · 2024: $295 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $236.55 | 2019-2022 | |
| Medtronic, INC. | $218.25 | 2022-2025 | Mazor X System |
| Vertex Pharmaceuticals Incorporated | $140.09 | 2025 | |
| Abbvie INC. | $132.60 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $101.76 | 2023-2024 | Andexxa |
| Alphatec Spine, INC | $85.64 | 2024 | Other - Miscellaneous |
| Stryker Corporation | $63.77 | 2022-2025 | Augment Injectable |
| Ucb, INC. | $53.17 | 2022-2024 | Briviact |
| Mimedx Group, INC. | $52.08 | 2024-2025 | |
| Kerecis Limited | $51.73 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Djo, LLC | $47.28 | 2023-2025 | Donjoy, Cmf |
| Nevro Corp. | $46.10 | 2024 | Senza |
| Zimmer Biomet Holdings, INC. | $40.17 | 2019-2022 | |
| Amgen INC. | $34.95 | 2022 | |
| Pfizer INC. | $32.36 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $27.16 | 2023 | Gliadel |
| Si-Bone, INC. | $25.44 | 2021-2022 | |
| Lilly USA, LLC | $22.52 | 2025 | Reyvow, Emgality |
| Merz Pharmaceuticals, LLC | $17.63 | 2024 | Xeomin |
| Boston Scientific Corporation | $13.68 | 2019 | |
| Neurocrine Biosciences, INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrita Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.